Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jun;33(3):740-50.
doi: 10.1007/s10637-014-0154-x. Epub 2014 Sep 12.

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Takayuki Yoshino  1 , Yoshito Komatsu, Yasuhide Yamada, Kentaro Yamazaki, Akihito Tsuji, Takashi Ura, Axel Grothey, Eric Van Cutsem, Andrea Wagner, Frank Cihon, Yoko Hamada, Atsushi Ohtsu
Affiliations
Clinical Trial

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Takayuki Yoshino et al. Invest New Drugs. 2015 Jun.

Abstract

Background: In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the efficacy and safety of regorafenib in Japanese and non-Japanese subpopulations in the CORRECT trial.

Methods: Patients were randomized 2 : 1 to regorafenib 160 mg once daily or placebo for weeks 1-3 of each 4-week cycle. The primary endpoint was OS. Outcomes were assessed using descriptive statistics.

Results: One hundred Japanese and 660 non-Japanese patients were randomized to regorafenib (n = 67 and n = 438) or placebo (n = 33 and n = 222). Regorafenib had a consistent OS benefit in the Japanese and non-Japanese subpopulations, with hazard ratios of 0.81 (95 % confidence interval [CI] 0.43-1.51) and 0.77 (95 % CI 0.62-0.94), respectively. Regorafenib-associated hand-foot skin reaction, hypertension, proteinuria, thrombocytopenia, and lipase elevations occurred more frequently in the Japanese subpopulation than in the non-Japanese subpopulation, but were generally manageable.

Conclusion: Regorafenib appears to have comparable efficacy in Japanese and non-Japanese subpopulations, with a manageable adverse-event profile, suggesting that this agent could potentially become a standard of care in patients with mCRC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves showing overall survival and progression-free survival in Japanese (a and b, respectively) and non-Japanese patients (c and d, respectively)
Fig. 2
Fig. 2
Maximum percentage change in target lesion size in (a) Japanese patients and (b) non-Japanese patients
Fig. 3
Fig. 3
Distribution of area under the concentration–time curve over a 24-h dosing interval (AUC0–24) of (a) regorafenib, (b) M2 and (c) M5 in Japanese and non-Japanese patients. Boxes represent the median and interquartile range of AUC0–24 of regorafenib, M2 and M5; whiskers represent the range between the lowest and highest values within 1.5 times the first and third quartiles. Dots represent outlying values greater than 1.5 times the third quartile
See this image and copyright information in PMC

References

    1. Globocan (2013) Colorectal cancer. Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 18 Aug. 2014
    1. Foundation for Promotion of Cancer Research (2013) Cancer statistics in Japan 2013. http://ganjoho.jp/pro/statistics/en/backnumber/2013_en.html. Accessed 4 June 2014
    1. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–2516. doi: 10.1093/annonc/mds236. - DOI - PubMed
    1. National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 3. 2014. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 4 July 2014
    1. National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology (NCCN guidelines): rectal cancer. Version 3. 2014. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed 4 July 2014

Publication types

MeSH terms